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For  many  years  chloroquine  was  used  as  a  prophylactic  agent  against  malaria,  and  more
recently as  a mild  immunosuppressive.  However,  due  to lengthy  treatment  periods,  adverse
effects have  become  apparent,  which  included  retinopathy.  The  structurally  related  hydrox-
ychloroquine  is less  toxic,  thought  to  be owing  to a  lower  tissue  accumulation  in  melanin
rich  areas.  This  study  primarily  focused  on  quantifying  melanin  binding  between  chloro-
quine  and  hydroxychloroquine  at physiological  pH  to  investigate  the  potential  link  between
binding  and  reported  toxicity.  In addition,  for the ﬁrst  time  this  study  quantiﬁed  the actual
extent  of adsorption  of chloroquine  and hydroxychloroquine  to melanin  and examined  the
desorption  proﬁle  of both  drugs  from  melanin  to demonstrate  the  afﬁnity  between  the  pig-hloroquine
ydroxychloroquine
epia
dsorption
esorption
ment and  the  solutes.  The  results  suggest  that there  is a difference  between  the  adsorption
afﬁnities  of chloroquine  and  hydroxychloroquine,  potentially  explaining  the  differences
in  bioaccumulation  in  retinal  tissue.  In  addition,  both  solutes  displayed  a strong  physical
attraction  to  the absorbent.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
The pigment melanin has been linked to a range of
athologies in association with drug binding and has con-
equently attracted much attention [26]. Skin and feather
elanin have evolved over millennia and there is little
oubt regarding its photoprotective role [18]. However, the
eason  for pigmentation elsewhere in the mammalian body
emains  speculative. Melanin has been suggested to act as
 free radical scavenger and iron regulator in the brain [8].
onditions such as Parkinson’s disease are associated with
he  disappearance of melanin from relevant tissues, but
hether this is a cause or consequence of the disease is
nclear  [10]. It therefore suggests that melanin may  hold
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http://creativecommons.org/licenses/by-nc-nd/3.0/).the key to at least a few pathologies. In this study, the
focus was  on the afﬁnity of melanin for the antimalarial
drug chloroquine, and if the difference in ocular toxicity
between it and a related analogue, hydroxychloroquine,
could be clariﬁed.
The  toxicity of a particular drug depends in part on its
mode of action and whether it accumulates or not [17].
Due  to tissue or organ speciﬁcity, an irreversibly bound
xenobiotic will not necessarily cause adverse effects, but
rather  just act as a deactivated reservoir. However, melanin
binding becomes dangerous when accumulation occurs in
regions  that the released drug could cause damage [17].
Many  drugs have been examined over the last
50 years and include phenothiazines, antibiotics, anti-
malarials, antirheumatics, antifolates, illicit drugs and
herbicides, which all have an afﬁnity towards melanin
[1,3,12,14,16,23–27,30].  Chloroquine (Fig. 1a) has been
monitored for many years due to adverse effects caused
through prolonged use. Discovered in 1934, through the
is is an open access article under the CC BY-NC-ND license
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 and (b)Fig. 1. (a) Chloroquine
modiﬁcation of the antimalarial drug atabrine, and ini-
tially  given the name resochin [15], chloroquine had high
antimalarial activity without the side effects of other cur-
rent  drugs at the time. Despite initial toxicity concerns, it
remained  a ﬁrst line defence for the treatment of malaria
for  many decades.
Malaria  is a parasitic disease affecting erythrocytes and
is  spread by female anopheles mosquitoes. It has become
one  of the most devastating diseases in the tropics affecting
millions of people annually [6]. Antimalarial medication,
including chloroquine, has been the frontline choice in this
battle.  However, because of over- and inappropriate use,
resistant  strains of the malarial parasite started to evolve,
diminishing the effects of the drug [6,15].
Nevertheless, alternative uses of chloroquine include
treatment of rheumatoid arthritis, discoid lupus erythe-
matosus and amoebic hepatitis [5]. Due to these conditions
requiring on-going treatment, there is a risk that toxicity
may  occur through long term exposure. Similarly, exceed-
ing  dosage limits and patient age have been associated
with side effects related to chloroquine therapy. One of
the  most severe adverse effects is retinopathy with symp-
toms  including central vision loss, scotomata, an alteration
in  the ﬁeld of vision, reading difﬁculties and reduced colour
perception [21].
The  structurally related hydroxychloroquine (Fig. 1b) is
considered to cause a lower degree of retinal damage than
seen  with chloroquine [9]. It has been found that hydrox-
ychloroquine has a lower tissue accumulation compared
with chloroquine, which may  translate into a decreased
tendency for causing corneal change [7]. The correlation
between the percentage of tissue accumulation and the
amount  of pigment in the eye suggests a relationship
between retinopathy and melanin. Due to the apparent
association between chloroquine accumulation in the eye
and  retinopathy, it was proposed that retinopathy caused
by  chloroquine was either due to its adsorption to ocular
melanin [11] or due to another pathophysiological pathway
caused  by chloroquine itself [32]. An alternative hypothesis
suggested that adsorption of chloroquine to melanin may
alter  the melanin granule which subsequently undermines
the  protecting role of melanin as a free radical scavenger,
thus leading to retinal toxicity [4]. As the adverse effects of
hydroxychloroquine use are not as severe, it has been spec-
ulated  that the afﬁnity of melanin for hydroxychloroquine
is not as strong as for chloroquine [7].
To date, the binding potential of melanin for chloro-
quine has been examined quite extensively [22,28–31]. hydroxychloroquine.
However, this study has gone one step further and made a
direct  comparison between chloroquine and its analogue,
hydroxychloroquine, in an attempt to resolve physiological
differences in toxicity. Although adsorption of chloro-
quine on one type of melanin has been reported before,
no  desorption data have been published. Therefore, the
desorption proﬁle has been examined for both compounds
and compared in relation to the differences seen in drug
toxicity.
2.  Materials and methods
2.1.  Melanin sample preparation
The  melanin used was isolated from native Australian
cuttleﬁsh Sepia apama and Sepia novaehollandiae (Valente
Seafoods, South Australia, Australia and SARDI, South
Australia, Australia) through dissection of the ink sac of
partially frozen animals. Freezing ensured granulation of
the  ink, facilitating easier recovery and minimising con-
tamination. The contents of the ink sacs were emptied and
treated  once in 0.9% saline solution, and then centrifuged.
The remaining pellet was  frozen at −80 ◦C, freeze dried,
ground into a ﬁne powder and stored in a desiccator. This
melanin will be referred to as Sepia melanin.
2.2. Chemicals
Chloroquine diphosphate was  obtained from Merck Pty.
Ltd  (Australia), while potassium phosphate was purchased
from The British Drug Houses Ltd (England) and hydrox-
ychloroquine sulphate was  sourced from Sigma–Aldrich
(USA).
2.3. Preparation of stock solutions
A potassium phosphate (pH 7.4) buffer solution was
prepared fresh at 20 mM concentrations prior to use.
Stock solutions of 3.1 mmol/L chloroquine and 3.0 mmol/L
hydroxychloroquine were prepared in the buffer solution.
The  phosphate buffer solution was  used as a blank to cor-
rect  for background in spectrophotometric measurements.2.4. Instrumentation
A  Varian Cary 50 ultraviolet/visible (UV/vis) spec-
trophotometer was used to determine chloroquine and
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ydroxychloroquine concentrations. Solution pH was  mea-
ured  using a Hanna potentiometer (Model: pH211
icroprocessor pH meter) ﬁtted with a microelectrode.
.5. Calibration curve
Chloroquine  solutions ranging from 0.0031, 0.039,
.078, 0.16 to 0.31 mmol/L were prepared in phosphate
uffer at pH 7.4 to generate standard curves of absorbance
t  255 nm against chloroquine concentration. Hydroxy-
hloroquine concentrations over the range 0.0030, 0.037,
.074,  0.15 and 0.30, were prepared as outlined above for
hloroquine. However, analysis was conducted using the
avelength at 340 nm.  All samples were diluted 40 times
ith  phosphate buffer for analysis. Standard curves were
roduced in triplicate in order to determine the inter-day
eproducibility.
.6.  Equilibration time for adsorption
An amount of 5 mg  of melanin was spiked with 5 mL
f  0.63 mmol/L chloroquine. Separate tubes were equili-
rated for periods of 10, 30, 60, 120, and 240 min. After
ach equilibration time, the samples were centrifuged at
770  × g for 4 min  and the chloroquine concentration in
he  supernatant was determined by comparison with the
tandard  curve using UV/vis spectrophotometry at 255 nm.
olutions  were measured against a melanin blank solution
ackground. All experiments henceforth were produced
n  triplicate to assess the variability. Hydroxychloroquine
quilibration was performed in the same manner using a
oncentration of 0.60 mmol/L and a wavelength of 340 nm.
.7.  Adsorption of chloroquine and hydroxychloroquine
o Sepia melanin
To  determine the adsorption capacity of melanin, a
eries  of concentrations of chloroquine and hydroxychloro-
uine were prepared ranging from 0.16 to 2.2 mmol/L
chloroquine) and 0.089 to 1.2 mmol/L (hydroxychloro-
uine). A 5 mg  portion of melanin was equilibrated with
 mL  of the speciﬁed concentration of chloroquine pre-
ared  in 20 mM potassium phosphate buffer for 2 h. The
amples were centrifuged at 4770 × g for 4 min  and the
upernatant removed and analysed using UV/vis spec-
rophotometry at 255 nm.  Solutions of hydroxychloroquine
ere prepared in a similar manner. However, only 1 mg  of
elanin  was used in a volume of 1 mL  due to limited solute
vailability. The solutions were analysed at 340 nm.
.8.  Equilibration time for desorption
In order to investigate the rate of desorption, an appro-
riate amount of Sepia melanin was equilibrated with
 mL  of 1.9 mmol/L chloroquine or 1 mL  of 1.5 mmol/L
ydroxychloroquine for 2 h. Subsequently, the samples
ere centrifuged and the supernatant was drawn off. This
as  followed by the addition of the same volume of the
uffer  solution to the melanin pellet in separate tubes
nd  allowed to equilibrate for periods of 0.5, 2, 4, 6 and
4  h. After centrifugation, the amount of chloroquine ory Reports 1 (2014) 963–968 965
hydroxychloroquine desorbed from melanin was deter-
mined  using UV/vis spectrophotometry.
2.9.  Desorption of chloroquine and hydroxychloroquine
from Sepia melanin
Initially  5 mg  of melanin was  saturated by equilibration
with 5 mL  of 1.9 mmol/L chloroquine prepared in 20 mM
potassium phosphate buffer at pH 7.4 for 2 h. The samples
were then centrifuged at 477 × g for 4 min  and the super-
natant removed. Five millilitres of fresh buffer solution was
then  used to resuspend the melanin and an additional 2 h
was  allowed for the samples to re-equilibrate. Centrifu-
gation followed and the supernatant removed. This step
was  repeated another 7 times. The supernatant from each
step  was measured using UV/vis spectrophotometry at a
wavelength of 255 nm to determine the concentration of
chloroquine released from melanin, and therefore demon-
strate  the rate of solute release into or by the phosphate
buffer. This was used as a measure of the afﬁnity between
melanin and chloroquine.
In  addition, a desorption isotherm was examined. Five
milligrams of melanin was equilibrated with 5 mL  of a spec-
iﬁed  concentration of chloroquine ranging from 0.31 to
2.2  mmol/L. The samples were prepared in 20 mM potas-
sium  phosphate buffer at pH 7.4 and equilibrated for 2 h.
After  this time, the total volume of each individual buffer
solution was  increased by 1/3rd and re-equilibrated for a
further  2 h. The samples were then centrifuged at 4770 × g
and  the supernatant removed and measured using UV/vis
spectrophotometry at 255 nm.
The same method was used to determine the desorption
of hydroxychloroquine from melanin as for chloro-
quine. However, when determining the isotherm, 1 mg  of
melanin  was equilibrated in 1 mL  of 1.8 mmol/L hydrox-
ychloroquine. All samples were analysed using UV/vis
spectrophotometry at a wavelength of 340 nm.
2.10.  Langmuir isotherms
The Langmuir adsorption isotherm was used to model
chloroquine-melanin adsorption data. For Langmuir the-
ory,  sorption is assumed to take place at a speciﬁc
homogeneous site and theoretically, a saturation point
would be reached beyond which no further sorption would
take  place [1,3]. The Langmuir adsorption equation has the
form,
q  = q(m)KC(eq)
1 + KC(eq)
where q is the amount of adsorbed solute (adsorbate)
(mg/g), q(m) and K are related to monolayer adsorption
capacity of adsorbent (melanin) and energy of adsorp-
tion respectively. C(eq) represents the equilibrium solution
concentration of the solute and was  found using the equa-adsorption equilibrium isotherm of q against C(eq) was gen-
erated  to ﬁnd the adsorptive capacity of melanin. The graph
of  C(eq) versus C(eq)/q was used to calculate q(m) from the
slope of the line (q(m) = 1/slope).
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The primary aim of the study was  to compare chloro-Fig. 2. Equilibration time of chloroquine and hydroxychloroquine at pH
7.4.
3. Results
3.1. Analytical method development
Standard curves of absorbance against solute concen-
tration were generated for pH 7.4 using both chloroquine
and hydroxychloroquine. The coefﬁcient of variation (CV)
of  the slopes for each standard curve (n = 3) was  less than
1.05%,  with each standard concentration having a CV of
less  than 3.00%. Each curve gave a linear ﬁt of at least
99.9% for 5 data points. The lower limit of quantiﬁcation
was 0.0031 mmol/L and 0.0030 mmol/L for chloroquine
and hydroxychloroquine respectively, with negligible vari-
ation.
3.2.  Adsorption of chloroquine and hydroxychloroquine
to Sepia melanin
The  adsorption capacity was determined at pH 7.4 and
an  equilibration time of 2 h was found to be adequate for
both  chloroquine and hydroxychloroquine and was used
henceforth (Fig. 2).Chloroquine  had an adsorption capacity of 0.87 mmol/g
while hydroxychloroquine gave 0.56 mmol/g (Fig. 3).
Fig. 3. (a) Adsorption isotherm of chloroquine and hydroxychloroquine fFig. 4. Desorption proﬁle for chloroquine and hydroxychloroquine on
melanin.
3.3. Desorption of chloroquine and hydroxychloroquine
from Sepia melanin
To  determine the relationship between the solute and
the  adsorbent, a desorption isotherm was  used. Known
concentrations of chloroquine were diluted after the initial
equilibration with melanin and allowed to re-establish a
new  equilibrium. It was  observed that both the adsorption
and desorption isotherms coincided with each other, indi-
cating  that there is a physical attraction between melanin
and  chloroquine.
A  series of sequential rinses were performed to assess
the  afﬁnity strength between chloroquine and melanin. The
initial  rinse displaced the highest percentage of solute at
7%,  with each sequential rinse removing less chloroquine.
The total amount of chloroquine lost from the surface of
melanin  was 0.15 mmol/g (18%) (Fig. 4).
A  similar pattern was apparent for hydroxychloro-
quine. However, a higher percentage was initially lost from
melanin  (11.5%) and resulted in a greater amount of solute
displacement overall at 0.13 mmol/g in relation to initial
adsorbed concentration.
4.  Discussionquine and hydroxychloroquine adsorption to determine if
that  could account for toxicity differences between the two
or melanin at pH 7 4. (b) Linear form of the Langmuir expression.
oxicolog
c
m
A
t
w
a
a
t
a
p
r
t
h
[
m
m
s
d
a
t
c
t
e
h
T
q
c
e
A
s
c
c
i
(
c
h
c
v
p
p
e
a
w
t
a
f
h
d
m
h
d
i
a
y
d
h
t
dR.L. Schroeder, J.P. Gerber / T
ompounds at physiological pH. To avoid complications,
elanin was carefully extracted from two native South
ustralian cuttleﬁsh; Sepia apama (Australian giant cut-
leﬁsh)  and Sepia novaehollandiae. In a previous study, it
as  demonstrated that proteins which have been widely
ccepted to be part of melanin are in all probability
dsorbed from surrounding tissue during isolation [20]. For
his  study, Sepia melanin was used as it is more readily
vailable and required very little treatment, whereas the
reparation procedure of mammalian melanin is a lot more
igorous  and raises concerns about preserving the struc-
ural  integrity of the pigment [19]. Synthetic melanins
ave been widely employed to investigate adsorption
2,22,27,29]. However, there is clear evidence that such
elanins are not structurally representative of native
elanins and therefore any data gathered is of debatable
igniﬁcance. Results have shown that dopamine melanin
esorbs substantial amounts of free base after numerous
ttempts to clean the pigment [20]. Though this observa-
ion  is intriguing in itself, dopamine being such an unstable
ompound under experimental conditions, it conﬁrmed
he need for careful consideration of the type of melanin
mployed in our studies.
The  risk of developing retinopathy is reduced with
ydroxychloroquine use compared with chloroquine [33].
herefore,  the adsorption capacity of melanin for chloro-
uine and hydroxychloroquine was investigated and
ompared to determine whether there was any differ-
nce in the extent of binding. Sepia melanin isolated from
ustralian cuttleﬁsh was used to examine the relation-
hip between the solutes and melanin. This melanin was
arefully extracted from the animals to minimise protein
ontamination.
Hydroxychloroquine had a substantially lower afﬁn-
ty  towards Sepia melanin than chloroquine at pH 7.4
45%  difference). This difference was thought to be the
onsequence of the small variation in the structure of
ydroxychloroquine compared to chloroquine. Hydroxy-
hloroquine has three basic functional groups with pKa
alues  of <4.0, 8.3 and 9.7, two of which would be
rotonated at pH 7.4. Similarly, chloroquine has three
Ka  values of 4.0, 8.4 and 10.2 [34]. Thus the differ-
nce between the two compounds is the presence of the
dditional hydroxyl group on hydroxychloroquine which
ould  impart a greater aqueous solubility [13]. Therefore,
he  adsorption equilibrium between the surface of melanin
nd  the hydroxychloroquine in solution may  be expected to
avour  the solvent compared to chloroquine. Intriguingly,
ydroxychloroquine does not result in extensive tissue
amage. The result therefore suggests that the toxicity
ay  be a consequence of the reduced binding capacity of
ydroxychloroquine compared to chloroquine, meaning it
oes  not bioaccumulate to the same extent.
Adsorption experiments demonstrated that at phys-
ological pH there was a signiﬁcant difference in the
dsorption capacity between chloroquine and hydrox-
chloroquine for melanin, potentially explaining the
ifferences in bioaccumulation in retinal tissue. However,
ow  the two drugs are released from the pigment and what
his  may  mean for long term side effects, as seen with the
evelopment of retinopathy, also needs to be considered.y Reports 1 (2014) 963–968 967
Therefore, the desorption proﬁle of both chloroquine
and hydroxychloroquine were examined at pH 7.4. As there
was  very little difference between the adsorption proﬁle
and  the established desorption proﬁle for both compounds,
it  was concluded that a physical attraction exists between
the  solute and the absorbent. This signiﬁes a reversible
ionic interaction, rather than chemical binding.
The next important aspect was  to assess the strength
of the relationship between melanin and chloroquine. This
was  examined by conducting sequential rinses with the
speciﬁed  bathing solution at 2 h intervals. The ﬁrst rinse
resulted in the largest loss of compound from the surface
of  the melanin, at 7%. Each subsequent rinse removed cor-
respondingly less material, with the ﬁnal amount being
only  0.8% after 7 treatments. A total of 82% of the origi-
nal  bound solute was still present on melanin (Fig. 4). The
trend  highlights the strong afﬁnity between chloroquine
and melanin, potentially indicating the role chloroquine
plays in retinopathy. Once melanin is bound, it is not
readily released, as demonstrated by the failure of succes-
sive  rinses to wash any appreciable amount off the surface.
Similar results were apparent for hydroxychloroquine.
However, hydroxychloroquine desorbed at a slightly faster
rate  than chloroquine, again indicating that the binding
capacity in aqueous medium is less (hydroxychloroquine
showed an overall loss of 26% compared to chloroquine at
18%).  However, whether this small difference is enough
to  explain the less toxic nature of hydroxychloroquine
remains unclear and warrants further investigation.
5. Conclusion
The relationship between melanin and hydroxychloro-
quine was  examined for the ﬁrst time and compared to
the  adsorption of chloroquine on melanin. Hydroxychloro-
quine was found to have a lower afﬁnity than chloroquine,
potentially explaining the differences in bioaccumulation
in retinal tissue. Furthermore, desorption proﬁles for both
chloroquine and hydroxychloroquine were derived, a novel
result,  and it was concluded that these solutes have a strong
physical interaction rather than chemical. Further studies
will  be needed to examine the surface relationship between
these  two compounds and melanin in order to gain a full
appreciation of the binding mechanisms.
Transparency document
The  Transparency document associated with this article
can be found in the online version.
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